Regeneron shares fall after FDA rejects eye disease treatment

View of Regeneron Pharmaceuticals headquarters in Tarrytown, New York. Lev Radin | LightRocket | Getty Images Actions from Regeneron fell nearly 9% on Tuesday, according to the U.S. Food and Drug Administration. refused to approve a higher-dose version of the company’s successful eye treatment. The company sought approval for an 8-milligram dose of its Eylea […]